# Huabo Biopharm

Source: https://onco.cc/companies/huabo-biopharm/  
OnCo record `huabo-biopharm` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Huabo Biopharm is a Shanghai antibody company whose bispecific HB0036 blocks PD-L1 and TIGIT at once so that exhausted T cells can attack the tumour.

## Summary

Huabo Biopharm (Shanghai Huaota Biopharmaceutical) is a Shanghai-based developer of monoclonal and bispecific antibodies. Its oncology pipeline includes HB0036, a bispecific antibody against PD-L1 and TIGIT that is in phase 1/2 trials in advanced solid tumours including non-small cell lung cancer, alongside HB0025 (PD-L1 and VEGF) and HB0017, an IL-17A antibody for psoriasis.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Shanghai Huaota Biopharmaceutical; Huaota Biopharm; 华奥泰生物
- Tags: drug-maker
- HQ: Shanghai
- Type: biotech

## Connected records

- drugs: [HB0036](https://onco.cc/drugs/hb0036/)
- trials: [A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors](https://onco.cc/trials/nct05417321/), [A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC](https://onco.cc/trials/nct07376629/), [A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor](https://onco.cc/trials/nct06758557/), [Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous](https://onco.cc/trials/nct07360132/), [Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous No](https://onco.cc/trials/nct07383116/)

---
JSON: https://onco.cc/api/v1/entities/huabo-biopharm.json